Filtered By:
Condition: Rheumatoid Arthritis

This page shows you your search results in order of date. This is page number 19.

Order by Relevance | Date

Total 493 results found since Jan 2013.

Use of Chinese herbal medicines by rheumatoid arthritis patients was associated with lower risk of stroke: A retrospective cohort study.
CONCLUSION: The CHMs use was associated with lower risk of stroke for RA patients, suggesting that it could be integrated into conventional therapy to prevent subsequent stroke incident. PMID: 31331548 [PubMed - in process]
Source: Complementary Therapies in Medicine - July 25, 2019 Category: Complementary Medicine Authors: Lai NS, Livneh H, Fan YH, Lu MC, Liao HH, Tsai TY Tags: Complement Ther Med Source Type: research

A Multicenter, Randomized, Placebo ‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis
ConclusionAtorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.
Source: Arthritis and Rheumatology - July 21, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J. F. Belch, Deborah P. M. Symmons, on behalf of the TRACE RA Consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Pete Tags: Original Article Source Type: research

Cardiovascular profile in osteoarthritis: A meta-analysis of cardiovascular events and risk factors
Conclusion: Our meta-analysis results revealed higher cardiovascular risk in OA patients. This highlights the importance of cardiovascular risk factor management in OA.
Source: Joint Bone Spine - July 17, 2019 Category: Orthopaedics Source Type: research

Circulating cell-free DNA fragment analysis by microchip electrophoresis and its relationship with DNase I in cardiac diseases
In this study, plasma cfDNA was extracted from the plasma of cardiac disease patients and the cfDNA fragment distribution as well as the relationships between cfDNA concentration and deoxyribonuclease I (DNase I) activity enzyme implicated in double-stranded DNA processing were examined. Results revealed that the cfDNA concentrations in patients with MI and cardiac angina were significantly higher than that in healthy control subjects. Microchip electrophoresis of plasma cfDNA revealed a single fragment (150–200 bp) in some healthy control subjects and three fragments (150–200 bp, 300–400 bp, and 500–600 bp...
Source: Clinica Chimica Acta - July 12, 2019 Category: Laboratory Medicine Source Type: research

Circulating cell-free DNA fragment analysis by microchip electrophoresis and its relationship with DNase I in cardiac diseases.
In this study, plasma cfDNA was extracted from the plasma of cardiac disease patients and the cfDNA fragment distribution as well as the relationships between cfDNA concentration and deoxyribonuclease I (DNase I) activity enzyme implicated in double-stranded DNA processing were examined. Results revealed that the cfDNA concentrations in patients with MI and cardiac angina were significantly higher than that in healthy control subjects. Microchip electrophoresis of plasma cfDNA revealed a single fragment (150-200 bp) in some healthy control subjects and three fragments (150-200 bp, 300-400 bp, and 500-600 bp) in all...
Source: International Journal of Clinical Chemistry - July 10, 2019 Category: Chemistry Authors: Fujihara J, Takinami Y, Ueki M, Kimura-Kataoka K, Yasuda T, Takeshita H Tags: Clin Chim Acta Source Type: research

WHO updates its essential medicines list, adds cancer and stroke drugs
The World Health Organization published an updated list of "essential medicines" on Tuesday, adding drugs for cancer, stroke, rheumatoid arthritis and inflammatory bowel disease among the treatments that should be seen as the standard.
Source: Reuters: Health - July 9, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Do rheumatoid arthritis patients have more major complications and length of stay after lower extremities fracture surgery?: A nationwide data with propensity score matching
Patients with rheumatoid arthritis (RA) have a high risk of cardiovascular diseases and fractures. This retrospective cohort study explored whether patients with RA face higher complication risks or longer hospital stays than other patients when they had a lower limb fracture that required the surgery. Patients aged>45 years who received lower limb fracture surgeries between 2005 and 2012 were selected from the National Health Insurance Research Database, and 10 related variables including sex and age were used in propensity score matching to pair RA patients with non-RA patients in a 1:4 ratio. The final study sample comp...
Source: Medicine - July 1, 2019 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population ‐based cohort study in Taiwan
ConclusionBiologics used in RA patients have been shown to have a beneficial impact on improving clinical outcomes, including decreased risks of death and stroke. The economic burden from costs of biologics may be alleviated by improving outcomes.
Source: International Journal of Rheumatic Diseases - June 24, 2019 Category: Rheumatology Authors: Chao ‐Hsiun Tang, Fun Yu, Ching‐Ya Huang, Der‐Yuan Chen Tags: ORIGINAL ARTICLE Source Type: research

Libman-Sacks endocarditis in a Bangladeshi patient suffering from rhupus.
We report such a patient, who had been diagnosed as having RA seven years before and had suffered an acute ischaemic stroke one year previously and had echocardiographic evidence of LSE found during routine evaluation. However, she tested negative for aPA. PMID: 31180802 [PubMed - as supplied by publisher]
Source: Tropical Doctor - June 9, 2019 Category: Tropical Medicine Authors: Zaman S, Rahim MA, Sayami LA, Nabi S, Islam AM, Ullah M Tags: Trop Doct Source Type: research

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
This study is active but not recruiting and is registered with ClinicalTrials.gov, number NCT02706951.FindingsPatients were screened between Feb 23, 2016, and May 19, 2017 and 648 were randomly assigned to treatment. 598 (92%) completed week 14. At week 14, an ACR20 response was achieved by 89 (41%) of 216 patients (95% CI 35–48) in the continued methotrexate group, 147 (68%) of 217 patients (62–74) receiving upadacitinib 15 mg, and 153 (71%) of 215 patients (65–77) receiving upadacitinib 30 mg (p<0·0001 for both doses vs continued methotrexate). DAS28(CRP) 3·2 or lower was met by 42 (19%) of 216 (95% CI 14–2...
Source: The Lancet - May 24, 2019 Category: General Medicine Source Type: research

Increasing Upstream Chromatin Long –Range Interactions May Favor Induction of Circular RNAs in LysoPC-Activated Human Aortic Endothelial Cells
We examined the sponging potential of all significantly changed circRNAs using the CircInteractome database (Montefiori et al., 2018), recording two miRNAs with four or more predicted binding sites in a single circRNA transcript, a threshold above which meaningful sponging activity is likely to occur Memczak et al. (2013). Another four significantly changed circRNAs are experimentally shown to sponge miRNAs (Dudekula et al., 2016; Chen et al., 2017; Yan et al., 2017; Wang et al., 2018), for six total circRNAs with miRNA sponging activity including miR125, miR143, miR1272, miR153, miR515-5p, and miR196a-5p (Table 4). In Fig...
Source: Frontiers in Physiology - April 17, 2019 Category: Physiology Source Type: research

Geniposide Alleviates Glucocorticoid-Induced Inhibition of Osteogenic Differentiation in MC3T3-E1 Cells by ERK Pathway
Conclusion In summary, we demonstrated that geniposide alleviated GC-induced osteogenic suppression in MC3T3-E1 cells. The effects of geniposide were at least partially associated with activating ERK signaling pathway via GLP-1 receptor. Geniposide might be a potential therapeutic agent for protection against GC-induced osteoporosis. Author Contributions BX, DX, CZ, and LW participated in research design. BX, JW, YL, XW, and ZZ conducted the experiments. BX, DX, and LW contributed new reagents or analytic tools and wrote or contributed to the writing of the manuscript. BX, JW, CZ, and DX performed the data analysis. Fu...
Source: Frontiers in Pharmacology - April 17, 2019 Category: Drugs & Pharmacology Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Subclinical Atherosclerosis in Primary Sj ögren's Syndrome: Does Inflammation Matter?
Conclusions The markers of endothelial activation and damage and of chronic inflammation investigated until now failed to result predictors of subclinical atherosclerosis or to be associated with increased risk of CV events in SS patients. This may suggest that other mechanisms are implicated with increased prevalence of subclinical atherosclerosis in SS or that these biomarkers exert a different mechanism in the pathogenesis of endothelial damage and in the induction of atherosclerosis. Surely, the relationship between the disease itself and inflammatory and immune dysfunction factors is quite complex and still to be cla...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long ‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
ConclusionIn this post ‐hoc analysis, after 24 weeks of tofacitinib, increased HDL‐c, but not increases in LDL‐c or TC, appeared to be associated with lower future MACE risk. Further data are needed to test the cardiovascular safety of tofacitinib.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 16, 2019 Category: Rheumatology Authors: Christina Charles ‐Schoeman, Ryan DeMasi, Hernan Valdez, Koshika Soma, Lie‐Ju Hwang, Mary G. Boy, Pinaki Biswas, Iain B. McInnes Tags: Full Length Source Type: research